Lataa...
Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization
Monoclonal antibodies (mAbs) and tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), which is often pathogenetically overexpressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised again...
Tallennettuna:
| Julkaisussa: | J Cell Mol Med |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Ltd
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4516546/ https://ncbi.nlm.nih.gov/pubmed/19432811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2009.00783.x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|